Total Payments
$2.3M
2024 Payments
$242,711
Companies
36
Transactions
2,181
Medicare Patients
3,743
Medicare Billing
$313,820
Payment Breakdown by Category
Other$1.8M (78.4%)
Consulting$245,053 (10.5%)
Travel$207,128 (8.8%)
Food & Beverage$53,540 (2.3%)
Education$284.09 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 370 | 54.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $334,250 | 83 | 14.3% |
| Consulting Fee | $245,053 | 69 | 10.5% |
| Travel and Lodging | $207,128 | 733 | 8.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $187,640 | 44 | 8.0% |
| Food and Beverage | $53,540 | 845 | 2.3% |
| Honoraria | $30,648 | 18 | 1.3% |
| Education | $284.09 | 19 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $627,697 | 600 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $522,654 | 463 | $0 (2024) |
| ABBVIE INC. | $251,503 | 254 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $151,353 | 79 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $120,123 | 122 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $91,572 | 95 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $80,037 | 80 | $0 (2019) |
| Dova Pharmaceuticals | $74,636 | 67 | $0 (2021) |
| Valeant Pharmaceuticals North America LLC | $73,970 | 64 | $0 (2017) |
| Eisai Inc. | $71,933 | 70 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $242,711 | 214 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($64,006) |
| 2023 | $259,994 | 254 | Gilead Sciences, Inc. ($59,279) |
| 2022 | $233,425 | 210 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($73,007) |
| 2021 | $211,150 | 184 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($97,187) |
| 2020 | $135,311 | 87 | Gilead Sciences, Inc. ($51,607) |
| 2019 | $463,529 | 447 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($125,232) |
| 2018 | $429,657 | 414 | Gilead Sciences, Inc. ($121,055) |
| 2017 | $366,516 | 371 | Gilead Sciences Inc ($109,251) |
All Payment Transactions
2,181 individual payment records from CMS Open Payments — Page 1 of 88
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,790.00 | General |
| Category: INFLAM | ||||||
| 12/18/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,115.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $11,025.00 | General |
| 12/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $140.00 | General |
| 12/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $140.00 | General |
| 12/16/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $138.46 | General |
| Category: INFLAM | ||||||
| 12/11/2024 | ORPHALAN INC | CUVRIOR (Drug) | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: Hepatology | ||||||
| 12/09/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Travel and Lodging | Cash or cash equivalent | $53.60 | General |
| Category: Gastroenterology | ||||||
| 12/09/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Travel and Lodging | Cash or cash equivalent | $30.82 | General |
| Category: Gastroenterology | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,750.00 | General |
| Category: Gastroenterology | ||||||
| 11/27/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Honoraria | Cash or cash equivalent | $2,523.00 | General |
| Category: Rare Disease | ||||||
| 11/22/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,046.00 | General |
| Category: Rare Disease | ||||||
| 11/22/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Rare Disease | ||||||
| 11/22/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Travel and Lodging | In-kind items and services | $50.92 | General |
| Category: Rare Disease | ||||||
| 11/21/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $111.49 | General |
| Category: Gastroenterology | ||||||
| 11/20/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,115.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $127.38 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $67.67 | General |
| Category: LIVER DISEASE | ||||||
| 11/19/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,046.00 | General |
| Category: Rare Disease | ||||||
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $288.22 | General |
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $138.24 | General |
| 11/19/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $123.06 | General |
| Category: Rare Disease | ||||||
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $49.95 | General |
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $45.90 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 817 | 1,090 | $718,794 | $66,167 |
| 2022 | 7 | 845 | 1,276 | $785,584 | $73,903 |
| 2021 | 9 | 978 | 1,548 | $861,610 | $86,410 |
| 2020 | 15 | 1,103 | 1,465 | $915,093 | $87,340 |
Total Patients
3,743
Total Services
5,379
Medicare Billing
$313,820
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 333 | 487 | $417,846 | $36,973 | 8.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 184 | 217 | $110,236 | $11,436 | 10.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 53 | 53 | $57,505 | $5,708 | 9.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 167 | 224 | $79,296 | $5,408 | 6.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 23 | 23 | $20,470 | $2,562 | 12.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 14 | $18,480 | $2,082 | 11.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 17 | $7,990 | $1,153 | 14.4% |
| 99422 | Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes | Facility | 2023 | 19 | 41 | $5,655 | $740.18 | 13.1% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Facility | 2023 | 12 | 14 | $1,316 | $105.98 | 8.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 339 | 485 | $416,130 | $36,692 | 8.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 243 | 416 | $147,264 | $11,355 | 7.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 78 | 78 | $84,630 | $8,502 | 10.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 44 | 46 | $60,720 | $7,805 | 12.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 27 | 53 | $36,040 | $4,659 | 12.9% |
| 99422 | Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes | Office | 2022 | 49 | 112 | $14,784 | $2,129 | 14.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 37 | 39 | $19,812 | $1,748 | 8.8% |
| 99422 | Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes | Facility | 2022 | 28 | 47 | $6,204 | $1,011 | 16.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 229 | 388 | $332,904 | $31,228 | 9.4% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 275 | 446 | $157,884 | $11,879 | 7.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 201 | 231 | $117,348 | $11,443 | 9.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 58 | 63 | $83,160 | $10,895 | 13.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 34 | 85 | $57,800 | $7,642 | 13.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 58 | 58 | $62,930 | $6,525 | 10.4% |
| 99422 | Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 11-20 minutes | Office | 2021 | 93 | 247 | $32,604 | $5,021 | 15.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 18 | 18 | $15,552 | $1,306 | 8.4% |
About Dr. Sammy Saab, MD
Dr. Sammy Saab, MD is a Transplant Surgery healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720008899.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sammy Saab, MD has received a total of $2.3M in payments from pharmaceutical and medical device companies, with $242,711 received in 2024. These payments were reported across 2,181 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.3M).
As a Medicare-enrolled provider, Saab has provided services to 3,743 Medicare beneficiaries, totaling 5,379 services with total Medicare billing of $313,820. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Transplant Surgery
- Other Specialties Internal Medicine, Surgery
- Location Los Angeles, CA
- Active Since 07/20/2006
- Last Updated 01/06/2025
- Taxonomy Code 204F00000X
- Entity Type Individual
- NPI Number 1720008899
Products in Payments
- XIFAXAN (Drug) $560,409
- Epclusa (Drug) $328,506
- Vemlidy (Drug) $154,827
- Mavyret (Drug) $154,823
- TERLIVAZ (Drug) $101,884
- OCALIVA (Drug) $95,340
- Doptelet (Drug) $74,636
- Lenvima (Drug) $71,902
- ZEPATIER (Drug) $63,409
- LIVTENCITY (Drug) $54,723
- MAVYRET (Drug) $53,433
- Cabometyx (Drug) $50,740
- Nexavar (Drug) $48,496
- Stivarga (Drug) $43,075
- IQIRVO (Drug) $33,002
- DOPTELET (Drug) $26,473
- OPDIVO (Biological) $23,607
- REZDIFFRA (Drug) $22,954
- OCA (Drug) $22,883
- Mulpleta (Drug) $17,002
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Transplant Surgery Doctors in Los Angeles
Linda Sher, Md, MD
Transplant Surgery — Payments: $341,448
Transplant Surgery $341,448
Steven-Huy Han, Md, MD
Transplant Surgery — Payments: $163,979
Transplant Surgery $163,979
Dr. Francisco Arabia, M.d, M.D
Transplant Surgery — Payments: $134,216
Transplant Surgery $134,216
Yuri Genyk, Md, MD
Transplant Surgery — Payments: $42,984
Transplant Surgery $42,984
Dr. Nicholas Nissen, M.d, M.D
Transplant Surgery — Payments: $22,907
Transplant Surgery $22,907
Dr. Kambiz Kosari, Md, MD
Transplant Surgery — Payments: $19,738
Transplant Surgery $19,738